Answers are grounded in this paper and cite their sources.
This model-based synthesis of the most recent evidence suggests that pharmacogenetic UGT1A1 testing prior to irinotecan-based chemotherapy dominates non-personalized colon cancer care in Germany. However, as structural uncertainty remains high, these results require validation in clinical practice, e.g. based on a managed-entry agreement.
No takes yet. Share an insight, caveat, or question.
Butzke et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: